公开(公告)号：US11834485B2

公开(公告)日：2023-12-05

申请号：US17234896

申请日：2021-04-20

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Jiaxi Wu ,  Tong Zhang ,  Samuel Davis ,  Nicolin Bloch

IPC分类号： C07K14/55 ,  A61K38/20 ,  A61K45/06 ,  C07K14/47 ,  C07K14/735 ,  C07K14/74 ,  A61K38/00

CPC分类号： C07K14/55 ,  A61K38/2013 ,  A61K45/06 ,  C07K14/4748 ,  C07K14/70535 ,  C07K14/70539 ,  A61K38/00 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/41

摘要： This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2Rα. The IL-2 variants may retain the ability in binding to or activating IL-2Rβ and/or IL-2Rβγ. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.

公开(公告)号：US12091440B2

公开(公告)日：2024-09-17

申请号：US17127380

申请日：2020-12-18

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Jiaxi Wu ,  Tong Zhang ,  Maria del Pilar Molina-Portela ,  Eric Smith ,  Chia-Yang Lin ,  Thomas Craig Meagher

IPC分类号： C07K14/55 ,  A61K35/17 ,  A61K38/00 ,  A61K38/20 ,  A61K47/68 ,  A61P35/00 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C07K14/74

CPC分类号： C07K14/55 ,  A61K35/17 ,  A61K38/2013 ,  A61K47/6849 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70539 ,  C07K14/7155 ,  A61K38/00 ,  C07K2319/30

摘要： The present disclosure relates to IL2 agonists with improved therapeutic profiles.

公开(公告)号：US20210324030A1

公开(公告)日：2021-10-21

申请号：US17234896

申请日：2021-04-20

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Jiaxi Wu ,  Tong Zhang ,  Samuel Davis ,  Nicolin Bloch

IPC分类号： C07K14/55 ,  C07K14/47 ,  C07K14/74 ,  A61K45/06 ,  A61K38/20 ,  C07K14/735

摘要： This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2Rα. The IL-2 variants may retain the ability in binding to or activating IL-2Rβ and/or IL-2Rβγ. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.

公开(公告)号：US20240148867A1

公开(公告)日：2024-05-09

申请号：US18497352

申请日：2023-10-30

申请人： Regeneron Pharmaceuticals, Inc.

发明人： David DiLillo ,  Jiaxi Wu

IPC分类号： A61K39/00

CPC分类号： A61K39/4611 ,  A61K39/4631 ,  A61K39/4632 ,  A61K39/464424 ,  A61K39/46447 ,  A61K39/464486 ,  A61K2239/39

摘要： The present disclosure relates to methods of increasing the efficacy of adoptive cell therapy (ACT) and methods of treating cancer, wherein the methods include administering to a subject with cancer in need thereof a combination therapy comprising a therapeutically effective amount of an ACT (e.g., an immune cell comprising a modified T cell receptor (TCR) against a tumor-associated antigen (TAA), or a chimeric antigen receptor (CAR) against a TAA) and a therapeutically effective amount of a targeted immunocytokine (e.g., a fusion protein comprising an IL2 moiety and an immunoglobulin antigen-binding domain that binds to PD1). The combination therapy demonstrates increased anti-tumor efficacy, increased duration of tumor control and/or increased overall survival, as compared to a subject administered the ACT as monotherapy or the ACT in combination with a non-targeted immunocytokine.

公开(公告)号：US20220402989A1

公开(公告)日：2022-12-22

申请号：US17806566

申请日：2022-06-13

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Jiaxi Wu ,  Nicolin Bloch ,  Tong Zhang ,  Chia-Yang Lin ,  Samuel Davis ,  Eric Smith ,  Erica Ullman

IPC分类号： C07K14/55 ,  C07K16/28 ,  C07K14/715 ,  A61P35/00

摘要： The present disclosure relates to a fusion protein comprising an antigen-binding moiety that binds specifically to human PD-1 and an IL2 moiety, and methods of use thereof.

公开(公告)号：US20240067690A1

公开(公告)日：2024-02-29

申请号：US18494355

申请日：2023-10-25

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Jiaxi Wu ,  Tong Zhang ,  Samuel Davis ,  Nicolin Bloch

IPC分类号： C07K14/55 ,  A61K38/20 ,  A61K45/06 ,  C07K14/47 ,  C07K14/735 ,  C07K14/74

CPC分类号： C07K14/55 ,  A61K38/2013 ,  A61K45/06 ,  C07K14/4748 ,  C07K14/70535 ,  C07K14/70539 ,  A61K38/00

摘要： This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2Rα. The IL-2 variants may retain the ability in binding to or activating IL-2Rβ and/or IL-2Rβγ. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.

公开(公告)号：US11725034B2

公开(公告)日：2023-08-15

申请号：US17709706

申请日：2022-03-31

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Jiaxi Wu ,  Tong Zhang ,  Maria del Pilar Molina-Portela ,  Eric Smith ,  Chia-Yang Lin ,  Thomas Craig Meagher

IPC分类号： C07K14/55 ,  A61K47/68 ,  A61P35/00 ,  C07K14/715 ,  A61K38/20 ,  A61K38/00 ,  A61K35/17 ,  C07K14/74 ,  C07K14/725 ,  C07K14/705

CPC分类号： C07K14/55 ,  A61K35/17 ,  A61K38/2013 ,  A61K47/6849 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70539 ,  C07K14/7155 ,  A61K38/00 ,  C07K2319/30

摘要： The present disclosure relates to IL2 agonists with improved therapeutic profiles.

公开(公告)号：US20230110958A1

公开(公告)日：2023-04-13

申请号：US17887565

申请日：2022-08-15

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Arielle Glatman Zaretsky ,  Jiaxi Wu ,  Tong Zhang ,  Sokol Haxhinasto ,  Nicolin Bloch

IPC分类号： C07K14/54 ,  C07K14/715

摘要： The present disclosure relates to IL27 receptor agonists with improved therapeutic profiles.